Customer Churn Risk: Change of Accounts Due to Severance of Affiliated Relationships
- Risk
- Existing distributors have monopolized supply rights relying on “affiliated relationships” with specific hospitals. However, if we acquire the distributor and sever this special relationship, the hospital loses its incentive to continue using our platform, presenting a risk of them switching (churning) to another distributor.
- Mitigation
- Overwhelming SCM Cost Reduction: Provide “economic incentives” to prevent hospitals from churning.
- We will share the lowered supply unit costs achieved through our large-scale logistics hub and group purchasing with the hospital (Shared Savings), and provide VMI services like surgical kitting for free or at a low fee.
- From the hospital’s perspective, since they can legally reduce logistics labor costs more than when utilizing existing affiliated distributors, there is no reason to churn.
- Digital Lock-in: Immediately after acquisition, strongly integrate our B2B ordering system with the hospital’s HIS (IT network) via API.
- Once the IT systems are integrated and nurses are quickly trained and accustomed to our system, switching costs skyrocket, practically generating a permanent lock-in effect.
Post-Merger Integration (PMI) Risk: System Integration Failure and Organizational Culture Clash
- Risk
- Due to the nature of the roll-up strategy, dozens of small businesses must be absorbed in a short period (within the 2-year grace period).
- During this process, there is an operational risk of delays when integrating data from companies using disparate programs or manual ledgers, or of sales networks being damaged due to pushback from existing personnel.
- Mitigation
- Centralized Control Centered on the Anchor: Rather than maintaining the existing systems of individual acquired companies, we will proceed with IT integration by migrating all master data to our (the anchor target’s) pre-introduced standard ERP/WMS within a certain period starting from the day of acquisition.
- Selective Retention and Performance Compensation of Core Sales Networks (Key-men): While proactively downsizing inefficient back-office and logistics personnel to create synergies, we will retain key sales personnel (Key-men) who have deep relationships with individual hospital directors and professors on our platform.
- We will provide them with a clear incentive structure (e.g., aggressive rewards for securing new orders from other hospitals using our system) to block sales leakages in the early stages of the deal.
Risk of Existing Large Players Entering the Medical Device/Therapeutic Material Distribution Market: Pharmaceutical Distributors and Large MRO Companies
- Risk
- The overwhelming #1 in pharmaceutical distribution, “Geo-Young” (MBK Partners), or the B2B MRO (Maintenance, Repair, and Operations) company “Serveone” (an Affinity Equity Partners portfolio company) already possess trillions of won in capital and nationwide logistics networks.
- There is a high probability that they will target the high-margin medical device and therapeutic material market as their Next Target and enter directly.
- If they induce bleeding competition by offering drastic unit price discounts to hospitals based on their massive financial power, the expansion of our platform’s market share may be limited, and profitability could deteriorate.
- Mitigants
- Fundamental Differences in Logistics Characteristics (High Barrier to Entry): Pharmaceutical and MRO logistics possess the characteristics of a Standardized Volume Game (i.e., moving standardized boxes from point A to B).
- On the other hand, therapeutic material logistics essentially requires highly specialized “In-hospital Operation” capabilities, such as pre-kitting tailored to surgical schedules, sterile inventory management within operating rooms, and close-contact VMI with nurses.
- No matter how large their warehouses are, it is impossible to dominate the market without clinical know-how and hospital information system (HIS) integration.
- Lock-in through Switching Costs: From the hospital’s perspective, it is difficult to quickly replace a platform (WMS/EDI) that is already integrated with the in-hospital system and managing inventory, simply in exchange for unit price discounts from a distributor.
- Turning Risk into Opportunity (Exit Target): In reality, this risk is replaced by our most powerful “Exit Equity Story.”
- For large players like Geo-Young or Serveone to directly enter a fragmented and complex market, the time and trial-and-error costs are too high.
- Therefore, they are highly likely to choose the method of acquiring a platform—which has already rolled up SME distributors and dominated hospital IT networks—at a premium, making our company the perfect M&A target.
Risk of Bypass Entry and Forward Integration: Direct Entry by “Manufacturers” and Hospital Bypassing
- Risk
- The affiliated transaction restriction provisions of the Dec 2025 Medical Device Act amendment apply only to sellers and lessors (i.e., wholesalers/distributors), while medical device manufacturers are excluded from regulation.
- Hospital Bypass Entry: Instead of closing the distributor (sales business), there is a possibility that a hospital director or foundation might establish a nominal “medical device manufacturer” to continue taking margins by directly supplying the hospital while maintaining the special relationship.
- Forward Integration by Existing Manufacturers: Existing medical device manufacturers may expand direct transactions with large hospitals to protect their margins from distributors (GPOs), posing a risk of bypassing GPOs like us.
- Mitigation
- High Difficulty of Manufacturing Licensing (Blocking Hospital Bypassing): Unlike the distribution business (wholesale), which only requires a business registration certificate, the medical device “manufacturing business” requires massive initial capital (CapEx) and time, including the MFDS’s strict GMP (Good Manufacturing Practice) certification, production facility construction, MFDS product approval, and clinical data submission.
- It is an unrealistic scenario for a hospital to actually establish or acquire a manufacturing plant solely for distribution margins, and a paper manufacturer existing only on documents faces the risk of immediate license cancellation during MFDS inspections.
- Hospitals’ Absolute Need for One-stop Sourcing: Even if an individual manufacturer attempts direct supply to a hospital, a large hospital requires tens of thousands of SKUs from hundreds of manufacturers for surgeries.
- Individually contracting, ordering, paying, and managing inventory by manufacturer can cause an overload on the hospital’s administrative and logistics systems.
- Hospitals inevitably have an absolute need for an “integrated GPO” that aggregates and manages goods from all manufacturers at once and unifies the payment window.
- Therefore, individual forward integration attempts by manufacturers inherently face fragmented limitations and can never threaten the position of our giant platform, which is armed with administrative convenience for hospitals and SCM efficiency.
Exit Strategy
Potential Buyers: Sale of an Infrastructure Asset that has Overcome Margin Normalization (Compression)
- Due to the Medical Device Act amendment and the strict application of the actual transaction price reimbursement system, the high margins (Spread) enjoyed by past distributors are highly likely to be compressed.
- However, we will transform the quality of earnings by 1) expanding profit scale through “overwhelming logistics volume” via roll-ups, 2) entering the non-reimbursable market, and 3) adopting a “fee-based/SaaS model” such as logistics outsourcing and data consulting.
- The platform, elevated to an “irreplaceable B2B healthcare infrastructure” that eliminates regulatory risks and generates stable lock-in cash flow, is deemed to be an attractive acquisition target for the following Strategic Investors (SIs) and Financial Investors (FIs).
Type 1: Strategic Investors (SI)
- Existing Ultra-Large Pharmaceutical-Based Distributors (Volume & Cross-selling Synergy)
- Potential Candidates: Geo-Young, Baekje Pharm, Zuellig Pharma, etc.
- Acquisition Incentives:
- Low-margin, high-volume capable players: They already possess the “economies of scale” DNA to generate trillion-won revenues and massive profits even with low margins (low-single digits) under the strict “actual transaction price reimbursement system” of the pharmaceutical market.
- Therefore, the normalization (decline) of medical device and therapeutic material distribution margins is not a serious demerit for them, and even high-single margins are perceived as relatively highly profitable.
- If they acquire our platform, they can immediately cross-sell our medical device and therapeutic material lineups to their existing network of thousands of hospitals and pharmacies, making us a surefire target to achieve extreme value-up by reducing remaining redundant costs through logistics network integration.
- Domestic Ultra-Large Conglomerates Aiming to Enter Healthcare and Big Data (Data & Tech Synergy)
- Potential Candidates: Kakao (Healthcare), Naver, SK (Discovery), Lotte (Healthcare), etc.
- Acquisition Incentives:
- Value of the Data Pipeline over Margin Rates: The candidates above prioritize securing B2B medical distribution data over the low-level box-moving that occurs during the distribution process.
- When we integrate VMI (automated inventory management) with hospital IT networks (HIS) to defend against margin declines, our platform evolves into a “data pipeline” capable of real-time queries on “what materials are consumed, when, and how much in operating rooms of large hospitals nationwide.”
- By acquiring us, conglomerates can secure top-tier domestic clinical and logistics big data and integrate it with their AI diagnostics, new drug development data, and B2C healthcare services, meaning they will be willing to pay a massive “platform/tech premium.”
- Global Ultra-Large GPOs and Healthcare Distribution Companies (Cross-border M&A)
- Potential Candidates: Cardinal Health, Medline, McKesson, etc. (US Top-tier)
- Acquisition Incentives:
- Incorporation into Global Standards: The candidates have eyed entry into Korea’s aging and aesthetics markets but have abandoned acquisitions due to the severe regulatory risks of Korean distributors, riddled with uncertainties from past affiliated relationships and rebates.
- However, assuming we transparently clean up the market through roll-ups and successfully transition the business model from simple distribution to an advanced “fee-based/shared savings” GPO model, our margin structure will become as transparent as global standards, giving them a strong motive to acquire us to secure an Asian healthcare hub.
Financial Investors (FI) – Multiple Re-rating Due to Improved Earnings Quality
- “Margin compression” due to the actual transaction price reimbursement system paradoxically creates higher valuation quality from an FI perspective.
- In capital markets, legal and permanent low margins combined with SaaS (software/management) fees are expected to be awarded much higher multiples than opaque, risk-based high margins.
- Global Mega-Cap PEs
- Potential Candidates: KKR, Blackstone, Carlyle, TPG, etc.
- Acquisition Incentives:
- LBO-Optimized Assets and Recurring Revenue: The core targets of the candidates above are “recession-proof essential goods” and “predictable cash flows.”
- Assuming our platform successfully replaces its margin source from a “regulatory blind spot” to “system subscription fees and logistics outsourcing fees through customer (hospital) lock-in,” the recurring revenue structure provides friendly fundamentals for utilizing large-scale acquisition financing.
- After acquiring us, based on their abundant financial power, they will formulate and execute even larger strategies, such as additional cross-border bolt-ons of non-reimbursable (aesthetics) distributors or overseas healthcare IT companies.
- Domestic Large-Cap PEs
- Potential Candidates: MBK Partners, Hahn & Co., IMM PE, etc.
- Acquisition Incentives:
- Replicating the Success Formula: MBK continuously generates profits through aggressive roll-ups and logistics efficiency, even in the actual transaction price reimbursement environment of pharmaceutical distribution (Geo-Young).
- They understand better than anyone the physiology that, even if margin rates slightly decrease in medical device distribution, the #1 operator holds absolute market dominance driven by economies of scale.
- After acquiring the primary platform from us (Secondary Buyout), they will utilize it as an anchor asset to completely roll up any remaining unintegrated regional hub distributors or drive a future IPO.
- ☞ The change in the regulatory environment, which compresses abnormal margins (Spread), is a death sentence for “fake distributors,” but for us, it is a perfect entry barrier to reorganize the market into a transparent “tech-based GPO infrastructure.”
- Our platform, having successfully replaced shadow profits with a legal volume and fee-based foundation, will break free from the limitations of a simple distributor (EV/EBITDA single digit x) and receive an overwhelming multiple re-rating as a healthcare IT/BPO platform (double digit x or higher), achieving a successful trillion-won exit.
Exit Equity Story: Normalization of the Abnormal, and Completion of an Irreplaceable Healthcare B2B Infrastructure
- The core of persuading future buyers consists of two powerful axes: Justification (ESG & Compliance) and Practicality (Scale & Quality of Earnings).
- Emphasize that the buyer is not just buying a simple company, but the “legal monopoly infrastructure of the South Korean medical ecosystem.”
- (ESG and Compliance) Elevation from a Shadow Broker to a Transparent Healthcare Infrastructure
- When global mega-funds and ultra-large conglomerates execute large-scale M&As, their biggest concerns are “regulatory risks” and “opaque corporate governance.”
- We will claim the highest premium on the fact that we have completely eliminated these risks through the entire roll-up process.
- Complete Institutionalization of the “Black Market” (Compliance-Cleared Asset)
- Emphasize that we have transformed the “abnormal distributor” ecosystem—previously tied to hospitals through special relationships and rife with unfair practices like consignment, toll fees, and rebates—into an “independent and transparent third-party GPO platform” that aligns with the intent of the 2025 Medical Device Act amendment.
- Prove that the UDI (Unique Device Identification)-based traceability system and transparent ordering (EDI) records we have built are “compliance” assets capable of passing fact-finding investigations by health authorities.
- ESG Equity Story Contributing to National Health Insurance Financial Savings
- We are not simply exploiting intermediary margins; rather, we are eliminating inefficiencies across the entire South Korean medical SCM ecosystem through the consolidation of logistics warehouses and optimization of delivery routes.
- Secure a strong social justification (Social Value) by sharing the lowered purchase costs with hospitals (patients) and national health insurance financial savings (Shared Savings).
- This is an attractive story that perfectly meets the strict investment criteria of global LPs (Limited Partners) and PEFs that prioritize ESG (Environmental, Social, and Governance) investments.
- (Scale and Fundamental Innovation) Dominating the Tech-enabled Ecosystem, Not Just Simple Box-Moving
- The overwhelming performance and qualitative improvement of the profit structure built upon this justification are firm fundamentals that guarantee the IRRs of FIs.
- Economies of Scale as the Overwhelming #1 and Lock-in Effects
- Elevated to a “mega vendor” handling a massive transaction volume in a fragmented market of thousands of small businesses.
- For manufacturers (Vendors), this overwhelming volume acts as a “powerful tollgate through which market entry is impossible without passing through us.”
- Simultaneously, as a result of closely integrating the IT networks (HIS) of hundreds of core hospitals with our Warehouse Management System (WMS), replacing our platform would cause paralysis in operating room inventory management for the hospitals, incurring high switching costs and establishing a strong “Digital Lock-in.”
- Qualitative Transformation of Profit Structure (From Spread to SaaS/Fee-based)
- Highlight that we have overcome the “distribution margin (Spread) shrinkage risk” caused by the government’s price cap reductions and the actual transaction price reimbursement system by pivoting our business model.
- Prove that we are not a simple wholesaler but a B2B healthcare IT solution company by successfully establishing a “Recurring Revenue” structure that lags economic cycles and is predictable—such as “SCM outsourcing fees” received for managing hospital logistics, data-driven “clinical purchasing consulting fees,” and margin upsides through dominating non-reimbursable and capital goods channels.
- ☞ Our equity story is completed by combining not only the financial achievement of growing in size by merging companies, but also the strong social and institutional justification of transforming an opaque distribution network—a national headache—into the “number one medical value chain platform in Korea” that is transparent, efficient, and compliant with regulations.
- This will serve as the logic to induce global PEFs or ultra-large SIs to pay a mega-platform premium that exceeds the average for simple distribution businesses when selling the giant integrated platform we have built in the future.
Multiples
Comparable Transaction Multiples (Transaction Multiples)
- (Unit: KRW million, %, x)
| # | Target | Date | Buyer | Seller | Transaction Amount | Stake (%) | EV | EBITDA | EV/EBITDA |
| ① | Geo-Young | 2024-04 | MBK Partners | Blackstone | 1,950,000 | 77.0% | 2,532,468 | 71,389 | 35.5 |
| ② | Via da Vinci | 2023-07 | Serveone(*) | Catholic Education Foundation | 360,000 | 51.0% | 705,882 | 147,821 | 4.8 |
| ③ | Geo-Young | 2019-04 | Blackstone | Anchor EP | 1,100,000 | 46.0% | 2,391,304 | 58,291 | 41.0 |
| ④ | Carecamp | 2014-06 | Geo-Young | Samsung C&T | 38,150 | 52.9% | 72,090 | 4,719 | 15.3 |
| ⑤ | Premier, Inc. | 2025-09 | Patient Square Capital | n.a. | 3,809,000 | 100.0% | 3,809,000 | 381,151 | 10.0 |
| ⑥ | Patterson Companies | 2024-12 | Patient Square Capital | n.a. | 5,248,770 | 100.0% | 5,248,770 | 451,081 | 11.6 |
- In the domestic market, pure GPOs are rare, and they are divided into large deals affiliated with Geo-Young and the Via da Vinci deal.
- In the case of Via da Vinci, it goes beyond a pure pharmaceutical wholesaler; it is a form where a large B2B logistics/MRO company absorbs medical distribution.
- Conversely, overseas, deals combining data, software, and multi-specialty networks beyond the purchasing agency function are active, and they are recognized with high valuations.
Via da Vinci ( ② ): Structural Arbitrage Targeting Tax/LDD Issues (EV/EBITDA single digit)
- The seller, the Catholic Education Foundation, had a unique circumstance where they were forced to dispose of a 51% stake to resolve massive gift tax risks and public interest corporation regulatory issues due to an excessive proportion of affiliated-party revenue (funneling work).
- Serveone targeted these legal vulnerabilities and the seller’s Tax Pain Points to acquire it at a low multiple.
Premier, Inc. & Patterson ( ⑤ , ⑥ ): Platform Valuation of Global Large GPOs (EV/EBITDA double digit)
- Patient Square Capital, a large PEF specializing in healthcare, consecutively took Premier (approx. KRW 3.8 trillion EV) and Patterson (approx. KRW 5.2 trillion EV) private in ’25.
- Bolt-on Strategy: As a tech-based GPO, Premier had continuously bolstered its scale by bolting on healthcare IT solutions like Stanson Health and IllumiCare, and Patterson also grew through steady roll-ups in the dental and animal health supply chain areas.
- The strategy that Patient Square Capital will also use these as core “platforms” in a fragmented supply chain market to deploy additional bolt-on M&As is reflected in the double-digit multiples.
Geo-Young ( ①③ ): Excessive Valuation Premium (EV/EBITDA 30+x)
- The monopolistic infrastructure value as the #1 domestic pharmaceutical distributor was reflected, but the entry multiple from a buyout perspective is excessively high.
- Practically, there is no room for Multiple Arbitrage, and since returns must rely solely on EBITDA volume growth, it is unrealistic as a benchmark target.
Carecamp ( ④ ): Outdated Deal (EV/EBITDA 15.3x)
- As the transaction occurred 10 years ago, it is past data that does not reflect the current distributor (GPO) market’s margin structure or regulatory environment, such as the ban on affiliated-party transactions, and is excluded from calculating the current fair multiple.
Investment Angle Based on Multiples
- Entry Strategy: Reasonable Baseline Entry (single digit)
- Unless it is a special situation involving tax issues like Via da Vinci (single digit x), we set the Target Entry Multiple at a single-digit EV/EBITDA level, including a realistic management premium.
- It is judged to be a structural valuation range that can convince sellers while taking an overwhelming price competitiveness compared to Geo-Young (30x+).
- Value Creation Plan (VCP): Scaling Up and SCM Advancement
- Active Bolt-on (Roll-up) Execution: Continuously acquire fragmented small-to-medium regional distributors to expand GMV volume.
- This directly translates into an expansion of Buying Power towards manufacturers, becoming the driving force to reduce supply costs and maximize the distribution spread.
- Advanced ERP Setup (Transition to Tech-enabled GPO): Immediately after acquisition, integrate the fragmented inventory and logistics systems of bolt-on targets into a single ERP.
- By reducing working capital burdens and logistics SG&A expenses, we fundamentally improve the constitution from a simple distribution wholesaler to a technology-based SCM platform.
- Exit Strategy: Realizing Multiple Arbitrage (10x+ Exit)
- Once bolt-ons and ERP setups are completed, we will be re-evaluated not as a small wholesaler but as a “large mega-platform GPO,” and it is judged that we can be awarded double-digit global peer multiples, similar to the cases of Premier and Patterson in the US.
- ☞ Under the structure of single-digit multiple entry → absolute EBITDA amount growth through Roll-up → ERP advancement → Exit at a double-digit multiple or higher, a scenario of generating returns from both ends—EBITDA Growth and Multiple Arbitrage—appears viable.